The purpose of this study was to examine changes in certain autoantibodies during progression to type 1 diabetes (T1D). Diabetes Prevention Trial-Type1 (DPT-1) participants were assessed for changes in these autoantibodies during the progression to T1D. Among 99 progressors to T1D with 2 specific autoantibody measurements at baseline and diagnosis, one autoantibody changed little or even decreased. In contrast, the other autoantibody increased substantially. The same patterns of change were also evident among those positive for both autoantibodies at baseline.
Jay M. Sosenko, MD, Jay S. Skyler, MD, Jerry P. Palmer, MD, Jeffrey P. Krischer, PHD, David Cuthbertson, MS, Liping Yu, MD, Desmond A. Schatz, MD, Tihamer Orban, MD, George Eisenbarth, MD, PHD and Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups. (2011) Diabetes Care. 34:2435-2437.
Ramifications for Individuals with Type 1 Diabetes:
Pancreatic autoantibodies are commonly present years before the diagnosis of type 1 diabetes (T1D), and they tend to occur according to a certain sequence. Yet there has been little known about changes in both autoantibody positivity and the amount of antibodies as the onset of T1D approaches. In the Diabetes Prevention Trial-Type 1 (DPT-1), serial measurements of autoantibodies were obtained for 99 progressors before diagnosis. These measurements, together with the large number of participants diagnosed with T1D in DPT-1, provided unique data for studying how autoantibody positivity and the amount of antibodies change over time with progression to T1D. The data indicate that more information about changes with progression to T1D can be obtained by examining changes in the amount of autoantibodies rather than just positivity. The differing patterns of change between specific autoantibodies in the years before diagnosis could be related to pathogenetic processes that are occurring during the progression to T1D.
This research was funded through NIH support of TrialNet. JDRF provides support to the International sites of TrialNet.